Physician profile
Timothy Robbins
NPI 1841945839
$3,081.24
in general payments reported to CMS, 2019-2025
18 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $134 · 2023: $492 · 2024: $1,960 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,212 · Travel and Lodging: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,211.67 |
| Travel and Lodging | $735.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,641.85 | 2024-2025 | Corevalve Evolut R |
| Boston Scientific Corporation | $274.67 | 2025 | Farapulse, Watchman Flx |
| Atricure, INC. | $255.01 | 2023-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Amgen INC. | $172.02 | 2022-2023 | Repatha, Evenity, Prolia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $125.38 | 2023-2024 | Lifevest |
| Esperion Therapeutics, INC. | $120.58 | 2022-2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $85.15 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $78.17 | 2023-2024 | Eliquis, Camzyos |
| Lexicon Pharmaceuticals, INC. | $58.16 | 2024 | |
| Novo Nordisk INC | $47.79 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Chiesi USA, INC. | $44.00 | 2024 | Kengreal |
| Merck Sharp & Dohme LLC | $37.52 | 2024 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $36.11 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $30.02 | 2023 | Farxiga |
| Briohealth Solutions, INC. | $24.69 | 2025 | Briovad |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $19.16 | 2023 | Optimizer |
| Hikma Pharmaceuticals USA | $16.10 | 2023 | Ryaltris |
| Scpharmaceuticals INC. | $14.86 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.